<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02327715</url>
  </required_header>
  <id_info>
    <org_study_id>FTC-02-prevention</org_study_id>
    <nct_id>NCT02327715</nct_id>
  </id_info>
  <brief_title>Emtricitabine for Prevention of Vertical Transmission of HBV in Chinese Pregnant HBsAg Positive Patients</brief_title>
  <official_title>Emtricitabine for Prevention of Vertical Transmission of HBV in Chinese Pregnant HBsAg Positive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asian-Pacific Alliance of Liver Disease, Beijing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Ditan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hebei Medical University Pharmaceutical Factory</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Health and Family Planning Commission, P.R.China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Asian-Pacific Alliance of Liver Disease, Beijing</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates generic emtricitabine(FTC) efficacy and safety in Chinese naive pregnant
      HBsAg positive patients in prevention of HBV vertical transmission. Single group patients
      were enrolled to receive emtricitabine till 24 weeks after delivery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single group patients were enrolled to receive emtricitabine till 24 weeks after delivery,
      which include HBeAg positive patients. Patients and their newborns were followed till 48
      weeks after delivery to evaluate the efficacy of prevention of vertical transmission.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HBsAg positive rate in newborns</measure>
    <time_frame>week48 after delivery</time_frame>
    <description>HBsAg positive rate in newborns</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>birth defect in newborns</measure>
    <time_frame>0 weeks, week24 and week48 after delivery</time_frame>
    <description>birth defect in newborns</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>virological response rate</measure>
    <time_frame>week 24 after delivery</time_frame>
    <description>HBV DNA &lt; 500 copies/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBV DNA decrease level</measure>
    <time_frame>week 24 after delivery</time_frame>
    <description>HBV DNA decrease compared with baseline（log10 copies/ml）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biochemical response</measure>
    <time_frame>week 24 after delivery</time_frame>
    <description>ALT normalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBeAg loss</measure>
    <time_frame>week 24 after delivery</time_frame>
    <description>HBeAg loss in HBeAg positive patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBeAg seroconversion</measure>
    <time_frame>week 24 after delivery</time_frame>
    <description>HBeAg seroconversion in HBeAg positive group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBV genetic resistance to emtricitabine</measure>
    <time_frame>week 24 after delivery</time_frame>
    <description>HBV genetic resistance to emtricitabine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse event</measure>
    <time_frame>week 24 after delivery</time_frame>
    <description>type and rate of adverse events;type and rate of severe adverse event</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>Chinese naive pregnant HBsAg positive patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single group patients were enrolled to receive emtricitabine(200mg one time per day) till 24 weeks after dilivery,patients and followed up for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emtricitabine</intervention_name>
    <description>emtricitabine were given to each patients from week 28 pregnancy to 24 weeks after delivery</description>
    <arm_group_label>Chinese naive pregnant HBsAg positive patients</arm_group_label>
    <other_name>Brand name：Huierding</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HBsAg positive for more than 6 months

          -  HBeAg positive patients: HBV DNA ≥ 5log10 copies/ml

          -  HBeAg postive patients: ALT≥2×ULN;or liver biopsy G≥2;or liver biopsy S ≥2;or liver
             biopsy Knodell HAI ≥ 4

          -  HBeAg negative patients: HBV DNA ≥ 4log10 copies/ml

          -  HBeAg postive patients: ALT≥2×ULN;or liver biopsy G≥2;or liver biopsy S ≥2;or liver
             biopsy Knodell HAI ≥ 4

          -  Nucleoside/nucleotide naive paitents

          -  Diagnosed as ≥ 28 weeks pregnancy

        Exclusion Criteria:

          -  Diagnosed HCC with AFP and ultrasound, CT or MRI

          -  Creatine ＞130μmol/L or Ccr &lt; 70mL/min

          -  Hemoglobin &lt;100g/L

          -  Coinfected with HAV,HEV,HCV,HDV or HIV

          -  ANA ＞ 1:100

          -  Uncontrolled cardiovascluar diseases, kidney diseases,lung diseases, neurological
             diseases, digestive diseases,metabolic disorders, immune-compromised diseases or
             cancer

          -  Drug abuse or alcohal addiction

          -  Previous history of taking agents of lamivudine, adefovir, tenofovir entecavir or
             telbivudine

          -  Long-term use of immunosuppressor or immunomodulator 6 months before enrollment to
             this trial

          -  Underwent liver transplantation or liver transplantation in schedule

          -  Allergic to nucleoside or nucleotide analogues

          -  family history of genetic defects disease

          -  Abnormal results in fatal defects screening

          -  HBsAg positive sperm provider pregnancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Cheng, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asian Pacific Alliance of Liver Diseases, Beijing</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jun Cheng, M.D.</last_name>
    <phone>+86 10 84322116</phone>
    <email>jun.cheng.ditan@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Song Yang, M.D.</last_name>
    <phone>+86 15011210692</phone>
    <email>sduyangsong@163.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Gish RG, Leung NW, Wright TL, Trinh H, Lang W, Kessler HA, Fang L, Wang LH, Delehanty J, Rigney A, Mondou E, Snow A, Rousseau F. Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimicrob Agents Chemother. 2002 Jun;46(6):1734-40.</citation>
    <PMID>12019083</PMID>
  </reference>
  <reference>
    <citation>Lim SG, Ng TM, Kung N, Krastev Z, Volfova M, Husa P, Lee SS, Chan S, Shiffman ML, Washington MK, Rigney A, Anderson J, Mondou E, Snow A, Sorbel J, Guan R, Rousseau F; Emtricitabine FTCB-301 Study Group. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med. 2006 Jan 9;166(1):49-56.</citation>
    <PMID>16401810</PMID>
  </reference>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2014</study_first_submitted>
  <study_first_submitted_qc>December 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2014</study_first_posted>
  <last_update_submitted>December 29, 2014</last_update_submitted>
  <last_update_submitted_qc>December 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis B virus</keyword>
  <keyword>Emtricitabine</keyword>
  <keyword>Pregnancy</keyword>
  <keyword>Vertical transmission</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emtricitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

